Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Strategic Positioning | Learn how MindMed's prudent approach to clinical trials and regulatory interactions could accelerate its path to market and bolster investor confidence |
Market Potential | Delve into the substantial opportunities in mental health therapeutics, with analyst price targets for MindMed ranging from $16 to $55 per share |
Clinical Milestones | Explore MindMed's progress in Phase 3 trials and the anticipation surrounding key readouts in 2026, potentially reshaping mental health treatment landscapes |
Psychedelic Pionee | MindMed leads the charge in developing psychedelic-inspired medicines for mental health, with a focus on Generalized Anxiety Disorder and Major Depressive Disorde |
Metrics to compare | MNMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMNMDPeersSector | |
---|---|---|---|---|
P/E Ratio | −8.1x | −1.0x | −0.5x | |
PEG Ratio | −0.12 | −0.02 | 0.00 | |
Price / Book | 2.8x | 1.1x | 2.6x | |
Price / LTM Sales | - | 2.0x | 3.2x | |
Upside (Analyst Target) | 148.1% | 124.6% | 46.0% | |
Fair Value Upside | Unlock | 13.9% | 6.3% | Unlock |